All In Biotech

Drug Trial Radar · NCT07712731

HPP737 in Adult Patients With Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Double-dummy, Active Drug Parallel-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of Oral HPP737 in Adult Patients With Moderate to Severe Plaque Psoriasis.

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 607 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

607

Actual

Start

Apr 18, 2025

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
Newsoara Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to an active control drug, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score and other standardized assessments? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to an active control drug (a positive drug comparator) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. This is a multicenter, randomized, double-blind, double-dummy, active-controlled Phase III clinical trial. Participants will: Take drug HPP737 or an active control drug orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) The trial plans to enroll approximately 606 participants across about 61 centers in China. Eligible participants are adults aged 18 years and older with a confirmed diagnosis of stable moderate-to-severe plaque psoriasis for at least 6 months.

Conditions

  • Psoriasis

Interventions

  • HPP737Drug

    HPP737 capsules for oral administration.

  • Placebo matching HPP737Drug

    Placebo capsules matching HPP737 for oral administration.

  • ApremilastDrug

    Apremilast tablets for oral administration.

  • Placebo matching ApremilastDrug

    Placebo tablets matching Apremilast for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75);Time frame: From enrollment to end of treatment at 16 weeks
  2. To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)"Time frame: From enrollment to end of treatment at 16 weeks

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Inner Mongolia Baogang Hospital

    Baotou, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Cangzhou People's Hospital

    Cangzhou, China

  • The Second Hospital of Jilin University

    Changchun, China

  • Changde First People's Hospital

    Changde, China

  • Third Xiangya Hospital of Central South University

    Changsha, China

  • The Second People's Hospital of Changzhi

    Changzhi, China

  • Affiliated Hospital of Chengde Medical College

    Chengde, China

  • Chengdu Second People's Hospital

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • Dalian Dermatology Hospital

    Dalian, China

  • Dermatology Hospital, Southern Medical University

    Guangzhou, China

  • Guangzhou First People's Hospital

    Guangzhou, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, China

  • Hainan Fifth People's Hospital

    Haikou, China

  • Hangzhou First People's Hospital

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, China

  • Dermatology Hospital, Shandong First Medical University

    Jinan, China

  • Jinan Central Hospital

    Jinan, China

  • Shandong Provincial Hospital

    Jinan, China

  • Jingzhou Central Hospital

    Jingmen, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, China

  • Lianyungang First People's Hospital

    Lianyungang, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • Jiangxi Provincial Dermatology Hospital

    Nanchang, China

  • Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • Hospital of Dermatology, Chinese Academy of Medical Sciences

    Nanjing, China

  • First Affiliated Hospital of Ningbo University

    Ningbo, China

  • Qingdao Traditional Chinese Medicine Hospital (Hai Ci Hospital)

    Qingdao, China

  • Qujing First People's Hospital

    Qujing, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Affiliated Central Hospital of Shenyang Medical College

    Shengyang, China

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.